综述:HBV感染者肝细胞癌早期检测的监测策略
本综述评估HBV感染者肝细胞癌监测策略,聚焦风险分层与早期检测进展。建议按指南风险标准筛选监测对象,年HCC风险低于0.2%者一般无需常规监测,符合标准者每6个月行超声联合或不联合AFP监测。GALAD、HES 2.0等新方法证据多来自混合病因队列,HBV特异性验证有限。
要点
- 年HCC风险低于0.2%的HBV感染者一般无需常规监测,应定期重新评估风险。
- 符合指南监测标准者每6个月行超声联合或不联合AFP监测。
- 风险预测评分用于风险评估,应与早期检测试验区分。
核心结论
- 应采用风险适配策略,将未来HCC风险评估与监测及早期检测试验分开。
- 符合指南标准者每6个月监测一次,新兴生物标志物、影像和人工智能方法仍为辅助性或研究性。
研究设计与样本
- 叙述性综述,检索PubMed和Cochrane数据库的英文文献。
- 评估HBV感染者HCC监测策略的效果,重点为早期HCC检测进展。
主要发现
- 总结与HCC易感性相关的病毒、宿主和环境因素。
- 评估当前超声联合或不联合AFP的监测方式。
- GALAD、HES 2.0、多靶点血液检测和简化MRI是有前景的早期检测方法。
关键数值与推荐
- 估计年HCC风险低于0.2%的患者一般不需要常规监测,应定期重新评估风险。
- 符合监测标准者每6个月行超声联合或不联合AFP监测。
临床怎么用
- 按指南风险标准筛选监测对象,年HCC风险低于0.2%者不常规监测。
- 符合标准者每6个月行超声联合或不联合AFP监测。
- 风险预测评分可用于风险评估,但不能替代早期检测试验。
局限性
- GALAD、HES 2.0、多靶点血液检测和简化MRI的支持证据多来自混合病因或非HBV队列。
- 上述方法的前瞻性HBV特异性验证仍有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Chronic hepatitis B virus (HBV) infection remains a major cause of hepatocellular carcinoma (HCC). Although antiviral therapy reduces cirrhosis and liver failure, HCC may still develop in patients with HBV, including in non-cirrhotic livers. This review aimed to evaluate current HCC surveillance strategies in HBV infection, focusing on risk stratification and advances in early detection. METHODS: English-language literature published in PubMed and the Cochrane Database was comprehensively reviewed. This narrative review assessed the effectiveness of HCC surveillance strategies in HBV-infected patients, with emphasis on recent advances in early-stage HCC detection. RESULTS: This review summarizes viral, host and environmental factors associated with HCC susceptibility and evaluates current surveillance using ultrasound with or without alpha-fetoprotein (AFP). Surveillance eligibility should follow guideline-defined risk criteria: patients with an estimated annual HCC risk below 0.2% generally do not require routine surveillance and should undergo periodic risk reassessment, whereas patients meeting surveillance criteria should undergo ultrasound with or without AFP every 6 months. Risk-prediction scores can refine assessment but should be distinguished from early-detection tests. GALAD, HES 2.0, multi-target blood tests, and abbreviated magnetic resonance imaging are promising early-detection approaches, but much of the supporting evidence derives from mixed-aetiology or non-HBV cohorts and prospective HBV-specific validation remains limited. CONCLUSION: A risk-adapted approach should separate estimation of future HCC risk from surveillance and early-detection testing. Guideline-eligible patients should undergo surveillance every 6 months, while emerging biomarker, imaging and artificial-intelligence approaches remain adjunctive or investigational pending further HBV-specific validation.
引用
- Park AJ, Pan BL, Pan X, et al. Review Article: Cancer Surveillance for Early Detection of Liver Cancer in Patients with HBV Infection. Aliment Pharmacol Ther. 2026. PMID: 42806894. doi:10.1111/apt.71008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。